The resolution seeks to suspend certain rules of the Texas House of Representatives to expedite the work of a conference committee on Senate Bill 2308, which proposes the establishment of a consortium for conducting clinical trials on ibogaine. This substance is being evaluated for FDA approval as a treatment for opioid use disorder and other related conditions. The resolution includes amendments to the bill that remove outdated definitions, introduce new relevant definitions, and outline the consortium's composition, which must include a drug developer, a higher education institution, and a hospital. It also allows for the removal of a grant program to create a more organized structure within the Health and Safety Code regarding ibogaine treatment.

Furthermore, the resolution stipulates that the consortium must secure matching funds from non-state sources before receiving state funding and requires members to submit an investigational new drug application to the FDA. It establishes reporting requirements for the consortium, including quarterly updates on progress and finances, and mandates that the Health and Human Services Commission report to the legislature annually. The resolution also clarifies the distribution of revenue from intellectual property rights generated by the trials, ensuring that at least 20% is allocated to the state. Finally, it directs the Health and Human Services Commission to start accepting proposals from consortiums within 60 days of the act's effective date, thereby facilitating the initiation of drug development trials in Texas.